Genes and symptoms in inherited bile flow problems
Part of Digestive system clinical trials.
This study looks at how genes affect bile flow problems in the liver. If you have a rare genetic condition like PFIC, researchers want to understand your specific type better by comparing your genes to your symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of a specific type of bile flow problem called PFIC, CCLD, or HBC (these are genetic conditions that cause cholestasis).
- You must be willing to sign a consent form to participate in the study.
- You cannot have another known liver disease that could explain your symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether certain family-related genes make people more likely to develop liver or bile duct cancers without a clear cause. If you had surgery or a transplant for one of these cancers and have had unexplained high liver enzymes or itching, this trial may help find genetic clues.
This study looks for new genes that might cause abnormal liver test results or specific bile duct diseases in adults, when standard testing hasn't found a clear cause. It also uses healthy blood donors as a comparison group.
This study tracks treatments and outcomes for people with a confirmed genetic form of PFIC, a rare liver disease. It helps doctors learn which treatments work best for each type.
This study looks at different genetic liver conditions called PFIC and follows how they progress over time. It also studies whether a procedure called biliary diversion may improve symptoms or long-term outcomes.
This study follows patients with PFIC (a rare liver disease affecting bile flow) who are taking or planning to take odevixibat (Bylvay), a medication that helps manage the condition. Researchers will track how well the medication works, any side effects, and long-term health outcomes in Chinese patients.
This study creates mini-livers (colangioids) from tiny tissue samples to find genetic reasons for atypical primary sclerosing cholangitis (aPSC), a rare liver disease. It aims to help doctors better understand and diagnose the condition.
Hear when a new Cholestatic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.